Pal, Rahul; Hom, Marisa E; van den Berg, Nynke S; Lwin, Thinzar M; Lee, Yu-Ji J; Prilutskiy, Andrey; Faquin, William; Yang, Eric; Saladi, Srinivas V; Varvares, Mark A; Rosenthal, Eben L; Kumar, Anand T N
description
Fluorescence molecular imaging, using cancer-targeted near infrared (NIR) fluorescent probes, offers the promise of accurate tumor delineation during surgeries and the detection of cancer specific molecular expression in vivo. However, nonspecific probe accumulation in normal tissue results in poor tumor fluorescence contrast, precluding widespread clinical adoption of novel imaging agents. Here we present the first clinical evidence that fluorescence lifetime (FLT) imaging can provide tumor specificity at the cellular level in patients systemically injected with panitumumab-IRDye800CW, an EGFR-targeted NIR fluorescent probe.
